TSX:OGI - CA68617J1003 - Common Stock
We assign a fundamental rating of 3 out of 10 to OGI. OGI was compared to 34 industry peers in the Pharmaceuticals industry. OGI has a bad profitability rating. Also its financial health evaluation is rather negative. OGI is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 1.38% | ||
ROE | 2.02% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | 3.47% | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.14 | ||
Debt/FCF | N/A | ||
Altman-Z | -0.33 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.59 | ||
Quick Ratio | 1.42 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 311.55 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
TSX:OGI (8/29/2025, 7:00:00 PM)
2.36
-0.02 (-0.84%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 311.55 | ||
P/S | 1.42 | ||
P/FCF | N/A | ||
P/OCF | 115.11 | ||
P/B | 0.82 | ||
P/tB | 1.12 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 1.38% | ||
ROE | 2.02% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | 3.47% | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.14 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 122.48% | ||
Cap/Sales | 8.8% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.59 | ||
Quick Ratio | 1.42 | ||
Altman-Z | -0.33 |